Company news

iBio, Inc. news in 2023

iBio, Inc.'s news releases, calls and decks from 2023, newest first.

View company

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

December 4, 2023

iBio Announces Reverse Stock Split

November 26, 2023

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

October 31, 2023

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

September 26, 2023

iBio Announces Amendment to Credit Agreement with Woodforest

September 20, 2023

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth

June 26, 2023

iBio Forges Research Collaboration with the National Institutes of Health

June 11, 2023

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

April 3, 2023

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

March 30, 2023

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

February 15, 2023

iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine

January 4, 2023

Decks in 2023